Colorectal Cancer

A potential biomarker to guide chemotherapy for metastatic colorectal cancer failed to stratify patients by progression-free survival or responsiveness to bevacizumab.

Marcovalerio Melis, MD, associate professor, Department of Surgery, NYU Langone Medical Center, discusses a study examining if surgery can be avoided in patients with advanced rectal cancer by using diffusion-weighted magnetic resonance imaging to predict pathologic response.

Patients with metastatic colorectal cancer (mCRC) had marginal yet inconsistent improvement in clinical outcomes when treated with a three-drug chemotherapy regimen plus bevacizumab compared with a doublet-bevacizumab regimen.

Adding panitumumab (Vectibix) to best supportive care reduced the risk of death by 30% for patients with RAS wild-type chemorefractory metastatic colorectal cancer.

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses sequencing regorafenib and TAS-102 for the treatment of patients with colorectal cancer.

Preoperative treatment with short-course radiation therapy plus 3 cycles of chemotherapy improved overall survival (OS) and was associated with fewer adverse events compared with standard chemoradiation for patients with locally advanced rectal cancer.

Jennifer Wu, MD, sheds light on TAS-102, as well as some emerging agents likely to play a role in the treatment of patients with colorectal cancer.

John L. Marshall, MD, discusses treatment advancements and other ongoing developments in colorectal cancer.

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, discusses the importance of genetic testing for colorectal cancer.

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses potential combinations with TAS-102 for the treatment of patients with colorectal cancer.

John Marshall, MD, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses curing colorectal cancer.

Contemporary efforts toward defining molecular subsets of colorectal cancer can potentially aid our ability to refine therapy and improve outcomes for patients with colorectal cancer.

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the potential for immunotherapy in colorectal cancer with mismatch repair deficiency.

John Marshall, MD, Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, Chief, Division Of Hematology/Oncology, Georgetown University Hospital Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses the importance of molecular testing in colorectal cancer.

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the efficacy of regorafenib and TAS-102 for the treatment of patients with colorectal cancer.

The FDA has granted a breakthrough therapy designation to pembrolizumab as a potential therapy for patients with microsatellite instability-high metastatic colorectal cancer.

Leonard Saltz, MD, discusses antiangiogenesis and the use of VEGF inhibitors in colorectal cancer.

ASCO has recommended extended RAS testing as a predictive biomarker of response for anti-EGFR monoclonal antibodies, further stressing the importance of broader molecular analyses for patients with metastatic colorectal cancer.

Dirk Arnold, MD, Director Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, Arnold Discusses the CONSIGN Study.

The FDA approved the oral nucleoside TAS-102 (Lonsurf) for the treatment of patients with advanced colorectal cancer, based on results from the phase III RECOURSE trial.